Common Contracts
2 similar Evaluation and Commercialization Agreement contracts by Genmab a/S
AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENTEvaluation and Commercialization Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
THIS AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENT (the “Agreement”), entered into as of July 12, 2012 (the “Execution Date”) but effective as of February 25, 1999 (the “Effective Date”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation with a place of business at Route 206 & Province Line Road, Princeton, NJ 08543 (“BMS”), Medarex, Inc., a New Jersey corporation and a wholly-owned subsidiary of BMS with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“Medarex, Inc.”), GenPharm International, Inc., a California corporation and a wholly-owned subsidiary of Medarex with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“GenPharm”) (all together “Medarex”), and Genmab A/S, a corporation organized and existing under the laws of Denmark, with a principal place of business at Bredgade 34, DK-1260 Copenhagen K, Denmark (“Genmab”).
AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENTEvaluation and Commercialization Agreement • April 2nd, 2019 • Genmab a/S • Pharmaceutical preparations
THIS AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENT (the “Agreement”), entered into as of July 12, 2012 (the “Execution Date”) but effective as of February 25, 1999 (the “Effective Date”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation with a place of business at Route 206 & Province Line Road, Princeton, NJ 08543 (“BMS”), Medarex, Inc., a New Jersey corporation and a wholly-owned subsidiary of BMS with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“Medarex, Inc.”), GenPharm International, Inc., a California corporation and a wholly-owned subsidiary of Medarex with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“GenPharm”) (all together “Medarex”), and Genmab A/S, a corporation organized and existing under the laws of Denmark, with a principal place of business at Bredgade 34, DK-1260 Copenhagen K, Denmark (“Genmab”).
